Overexpression of MIR-155 causes expansion, arrest in terminal differentiation and functional activation of mouse natural killer cells

Blood

Volumn 121, Issue 16, 2013, Pages 3126-3134

  Trotta, Rossana ^a   Chen, Li ^a   Costinean, Stefan ^b   Josyula, Srirama ^a   Mundy Bosse, Bethany L ^a   Ciarlariello, David ^a   Mao, Charlene ^a   Briercheck, Edward L ^b   McConnell, Kathleen K ^a   Mishra, Anjali ^a   Yu, Lianbo ^b   Croce, Carlo M ^a,b   Caligiuri, Michael A ^a,b,c  

^a OHIO STATE UNIVERSITY   (United States)

^b OHIO STATE UNIVERSITY   (United States)

^c THE OHIO STATE UNIVERSITY WEXNER MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIN; BROXURIDINE; CD11B ANTIGEN; CD27 ANTIGEN; CD3 ANTIGEN; GAMMA INTERFERON; GRANZYME; GRANZYME B; GRANZYME M; INTERLEUKIN 12; INTERLEUKIN 15; INTERLEUKIN 18; INTERLEUKIN 2; MICRORNA 155; MITOGEN ACTIVATED PROTEIN KINASE; PERFORIN; PHOSPHATASE; PROTEIN KINASE B; PROTEIN KINASE LCK; SH2 CONTAINING 5' INOSITOL PHOSPHATASE 1; UNCLASSIFIED DRUG; INOSITOL 1,4,5 TRISPHOSPHATE 5 PHOSPHATASE; INOSITOL-1,4,5-TRISPHOSPHATE 5-PHOSPHATASE; MICRORNA; MIRN155 MICRORNA, MOUSE;

ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CONTROL; CELL ACTIVATION; CELL DIFFERENTIATION; CELL EXPANSION; CELL STIMULATION; CELL SURVIVAL; CELL TRANSFER; CONJUGATION; CONTROLLED STUDY; CYTOTOXICITY ASSAY; FLOW CYTOMETRY; GENE OVEREXPRESSION; IMMUNOBLOTTING; IN VITRO STUDY; IN VIVO STUDY; LYMPHOMA; LYMPHOMA CELL LINE; MOUSE; NATURAL KILLER CELL; NONHUMAN; P815 CELL LINE; PHENOTYPE; PRIORITY JOURNAL; PROMOTER REGION; REGULATORY MECHANISM; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TARGET CELL; TUMOR GROWTH; ANIMAL; C57BL MOUSE; CELL COUNT; CELL CULTURE; CYTOLOGY; DOWN REGULATION; GENETICS; IMMUNOLOGY; METABOLISM; PATHOLOGY; SIGNAL TRANSDUCTION; TRANSGENE; TUMOR CELL LINE; UPREGULATION;

ANIMALS; CELL COUNT; CELL DIFFERENTIATION; CELL LINE, TUMOR; CELL SURVIVAL; CELLS, CULTURED; DOWN-REGULATION; INTERFERON-GAMMA; INTERLEUKIN-15; KILLER CELLS, NATURAL; LYMPHOMA; MAP KINASE SIGNALING SYSTEM; MICE; MICE, INBRED C57BL; MICRORNAS; PHOSPHORIC MONOESTER HYDROLASES; PROTO-ONCOGENE PROTEINS C-AKT; TRANSGENES; UP-REGULATION;

MLCS; MLOWN;

EID: 84879147532     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2012-12-467597     Document Type: Article

References (43)

1. Caligiuri MA. Human natural killer cells. Blood. 2008;112(3):461-469.
2. Huntington ND, Vosshenrich CA, Di Santo JP. Developmental pathways that generate naturalkiller- cell diversity in mice and humans. Nat Rev Immunol. 2007;7(9):703-714.
3. Kim S, Iizuka K, Kang HS, Dokun A, French AR, Greco S, Yokoyama WM. In vivo developmental stages in murine natural killer cell maturation. Nat Immunol. 2002;3(6):523-528.
4. Vosshenrich CA, Samson-Villéger SI, Di Santo JP. Distinguishing features of developing natural killer cells. Curr Opin Immunol. 2005;17(2):151-158.
5. Chiossone L, Chaix J, Fuseri N, Roth C, Vivier E, Walzer T. Maturation of mouse NK cells is a 4- stage developmental program. Blood. 2009; 113(22):5488-5496.
6. Hayakawa Y, Smyth MJ. CD27 dissects mature NK cells into two subsets with distinct responsiveness and migratory capacity. J Immunol. 2006;176(3):1517-1524.
7. Bezman NA, Cedars E, Steiner DF, Blelloch R, Hesslein DG, Lanier LL. Distinct requirements of microRNAs in NK cell activation, survival, and function. J Immunol. 2010;185(7):3835-3846.
8. Hesslein DG, Lanier LL. Transcriptional control of natural killer cell development and function. Adv Immunol. 2011;109:45-85.
9. Sullivan RP, Leong JW, Schneider SE, Keppel CR, Germino E, French AR, Fehniger TA. MicroRNA-deficient NK cells exhibit decreased survival but enhanced function. J Immunol. 2012; 188(7):3019-3030.
10. Tassi I, Cella M, Gilfillan S, Turnbull I, Diacovo TG, Penninger JM, Colonna M. p110gamma and p110delta phosphoinositide 3-kinase signaling pathways synergize to control development and functions of murine NK cells. Immunity. 2007; 27(2):214-227.
11. Baltimore D, Boldin MP, O'Connell RM, Rao DS, Taganov KD. MicroRNAs: new regulators of immune cell development and function. Nat Immunol. 2008;9(8):839-845.
12. Tili E, Croce CM, Michaille JJ. miR-155: On the crosstalk between inflammation and cancer. Int Rev Immunol. 2009;28(5):264-284.
13. Rodriguez A, Vigorito E, Clare S, et al. Requirement of bic/microRNA-155 for normal immune function. Science. 2007;316(5824): 608-611.
14. Thai TH, Calado DP, Casola S, et al. Regulation of the germinal center response by microRNA- 155. Science. 2007;316(5824):604-608.
15. Trotta R, Chen L, Ciarlariello D, et al. miR-155 regulates IFN-g production in natural killer cells. Blood. 2012;119(15):3478-3485.
16. Ranganathan P, Heaphy CE, Costinean S, et al. Regulation of acute graft-versus-host disease by microRNA-155. Blood. 2012;119(20):4786-4797.
17. Blaser BW, Schwind NR, Karol S, et al. Transpresentation of donor-derived interleukin 15 is necessary for the rapid onset of acute graftversus- host disease but not for graft-versus-tumor activity. Blood. 2006;108(7):2463-2469.
18. Cao X, Shores EW, Hu-Li J, et al. Defective lymphoid development in mice lacking expression of the common cytokine receptor gamma chain. Immunity. 1995;2(3):223-238.
19. Trotta R, Parihar R, Yu J, et al. Differential expression of SHIP1 in CD56bright and CD56dim NK cells provides a molecular basis for distinct functional responses to monokine costimulation. Blood. 2005;105(8):3011-3018.
20. Trotta R, Puorro KA, Paroli M, Azzoni L, Abebe B, Eisenlohr LC, Perussia B. Dependence of both spontaneous and antibody-dependent, granule exocytosis-mediated NK cell cytotoxicity on extracellular signal-regulated kinases. J Immunol. 1998;161(12):6648-6656.
21. Dong Z, Davidson D, Pérez-Quintero LA, Kurosaki T, Swat W, Veillette A. The adaptor SAP controls NK cell activation by regulating the enzymes Vav-1 and SHIP-1 and by enhancing conjugates with target cells. Immunity. 2012; 36(6):974-985.
22. Trotta R, Vignudelli T, Candini O, et al. BCR/ABL activates mdm2 mRNA translation via the La antigen. Cancer Cell. 2003;3(2):145-160.
23. Cooper MA, Bush JE, Fehniger TA, et al. In vivo evidence for a dependence on interleukin 15 for survival of natural killer cells. Blood. 2002; 100(10):3633-3638.
24. Guimond M, Freud AG, Mao HC, et al. In vivo role of Flt3 ligand and dendritic cells in NK cell homeostasis. J Immunol. 2010;184(6):2769-2775.
25. Kennedy MK, Glaccum M, Brown SN, et al. Reversible defects in natural killer and memory CD8 T cell lineages in interleukin 15-deficient mice. J Exp Med. 2000;191(5):771-780.
26. Fehniger TA, Suzuki K, Ponnappan A, et al. Fatal leukemia in interleukin 15 transgenic mice follows early expansions in natural killer and memory phenotype CD81 T cells. J Exp Med. 2001; 193(2):219-231.
27. Yu J, Wei M, Mao H, et al. CD94 defines phenotypically and functionally distinct mouse NK cell subsets. J Immunol. 2009;183(8):4968-4974.
28. Diefenbach A, Jensen ER, Jamieson AM, Raulet DH. Rae1 and H60 ligands of the NKG2D receptor stimulate tumour immunity. Nature. 2001;413(6852):165-171.
29. Rohrschneider LR, Fuller JF, Wolf I, Liu Y, Lucas DM. Structure, function, and biology of SHIP proteins. Genes Dev. 2000;14(5):505-520.
30. Jiang K, Zhong B, Gilvary DL, Corliss BC, Hong- Geller E, Wei S, Djeu JY. Pivotal role of phosphoinositide-3 kinase in regulation of cytotoxicity in natural killer cells. Nat Immunol. 2000;1(5):419-425.
31. Sun JC, Lanier LL. NK cell development, homeostasis and function: Parallels with CD81 T cells. Nat Rev Immunol. 2011;11(10):645-657.
32. Yokoyama WM, Kim S, French AR. The dynamic life of natural killer cells. Annu Rev Immunol. 2004;22:405-429.
33. Wang JW, Howson JM, Ghansah T, et al. Influence of SHIP on the NK repertoire and allogeneic bone marrow transplantation. Science. 2002;295(5562):2094-2097.
34. Lanier LL. Up on the tightrope: natural killer cell activation and inhibition. Nat Immunol. 2008;9(5): 495-502.
35. Shresta S, MacIvor DM, Heusel JW, Russell JH, Ley TJ. Natural killer and lymphokine-activated killer cells require granzyme B for the rapid induction of apoptosis in susceptible target cells. Proc Natl Acad Sci USA. 1995;92(12):5679-5683.
36. Fehniger TA, Cai SF, Cao X, Bredemeyer AJ, Presti RM, French AR, Ley TJ. Acquisition of murine NK cell cytotoxicity requires the translation of a pre-existing pool of granzyme B and perforin mRNAs. Immunity. 2007;26(6):798-811.
37. Fehniger TA, Wylie T, Germino E, et al. Nextgeneration sequencing identifies the natural killer cell microRNA transcriptome. Genome Res. 2010; 20(11):1590-1604.
38. Ruggeri L, Capanni M, Urbani E, et al. Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Science. 2002;295(5562):2097-2100.
39. Galandrini R, Tassi I, Mattia G, Lenti L, Piccoli M, Frati L, Santoni A. SH2-containing inositol phosphatase (SHIP-1) transiently translocates to raft domains and modulates CD16-mediated cytotoxicity in human NK cells. Blood. 2002; 100(13):4581-4589.
40. Thierfelder WE, van Deursen JM, Yamamoto K, et al. Requirement for Stat4 in interleukin-12-mediated responses of natural killer and T cells. Nature. 1996;382(6587): 171-174.
41. Parihar R, Trotta R, Roda JM, Ferketich AK, Tridandapani S, Caligiuri MA, Carson WE III. Src homology 2-containing inositol 59-phosphatase 1 negatively regulates IFN-gamma production by natural killer cells stimulated with antibody-coated tumor cells and interleukin-12. Cancer Res. 2005; 65(19):9099-9107.
42. Rajewsky N. microRNA target predictions in animals. Nat Genet. 2006;38(Suppl):S8-S13.
43. Chen Y, Zhu X, Zhang X, Liu B, Huang L. Nanoparticles modified with tumor-targeting scFv deliver siRNA and miRNA for cancer therapy. Mol Ther. 2010;18(9):1650-1656.